{"gene":"OVOL1","run_date":"2026-06-10T05:19:53","timeline":{"discoveries":[{"year":2006,"finding":"Ovol1 represses c-myc transcription by directly binding to the c-myc promoter, thereby promoting growth arrest of embryonic epidermal progenitor cells transitioning from proliferation to terminal differentiation.","method":"Chromatin immunoprecipitation (ChIP), reporter assays, Ovol1 knockout mouse model with keratinocyte proliferation assays","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — direct promoter binding shown by ChIP, functional rescue experiments in KO model, multiple orthogonal methods","pmids":["16636146"],"is_preprint":false},{"year":2005,"finding":"Ovol1 represses Id2 (inhibitor of differentiation 2) transcription in pachytene spermatocytes, and its loss causes failure to progress through the pachytene stage of meiotic prophase accompanied by aberrant cyclin B1 nuclear localization.","method":"Ovol1 knockout mouse model, transcriptional profiling, northern blot, reporter assays","journal":"Development (Cambridge, England)","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — KO model with defined cellular phenotype, reporter assays confirming Id2 as direct target, multiple orthogonal methods","pmids":["15716349"],"is_preprint":false},{"year":2007,"finding":"Ovol1 represses its own transcription (auto-repression) by: (1) competing with transcription activator c-Myb for DNA binding at its promoter, and (2) recruiting histone deacetylase (HDAC) activity via an N-terminal SNAG repressor domain.","method":"Reporter assays, chromatin immunoprecipitation (ChIP) for histone acetylation and c-Myb/Ovol1 occupancy, domain mutagenesis","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — multiple orthogonal methods (ChIP, reporter assays, domain mutagenesis) in single study","pmids":["17311813"],"is_preprint":false},{"year":2006,"finding":"Ovol1 represses Ovol2 promoter activity in a DNA binding-dependent manner; Ovol2 expression is upregulated in Ovol1-deficient epidermis, identifying Ovol2 as a direct downstream transcriptional target of Ovol1.","method":"Ovol1 knockout mouse model, reporter assays with Ovol2 promoter, DNA-binding mutant analysis","journal":"Biochimica et biophysica acta","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — KO model plus reporter assay with DNA-binding mutant, single lab but two orthogonal methods","pmids":["17049212"],"is_preprint":false},{"year":2013,"finding":"OVOL1 and OVOL2 induce mesenchymal-to-epithelial transition (MET) in human cancer cells through a regulatory feedback loop with EMT-inducing transcription factor ZEB1, and by inducing Epithelial Splicing Regulatory Protein 1 (ESRP1). Expression of OVOL-TFs in mesenchymal prostate cancer cells attenuates metastatic potential in mouse models.","method":"Overexpression in cancer cells, mouse prostate tumor models, expression analysis in 917 cancer cell lines","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — functional overexpression in cell lines and in vivo mouse model, but molecular mechanism of ZEB1 regulation not fully resolved at mechanistic detail level","pmids":["24124593"],"is_preprint":false},{"year":2017,"finding":"AHR activation upregulates OVOL1 expression in keratinocytes, and OVOL1 in turn regulates filaggrin (FLG) expression; IL-4 treatment inhibits nuclear translocation of OVOL1 in an atopic dermatitis model.","method":"OVOL1 overexpression and knockdown in normal human epidermal keratinocytes (NHEKs), AHR ligand treatment, nuclear translocation assays","journal":"Cell death & disease","confidence":"High","confidence_rationale":"Tier 2 / Moderate — gain- and loss-of-function experiments with defined molecular pathway (AHR→OVOL1→FLG), nuclear translocation assay, single lab but multiple orthogonal approaches","pmids":["28703805"],"is_preprint":false},{"year":2022,"finding":"OVOL1 interacts with and prevents ubiquitination and degradation of SMAD7, thereby stabilizing SMAD7 (a negative regulator of TGF-β type I receptor), leading to enhanced degradation of TGF-β type I receptor and inhibition of TGF-β/SMAD signaling. BMP promotes OVOL1 expression, which enhances BMP signaling in a positive feedback loop.","method":"Co-immunoprecipitation, ubiquitination assays, overexpression/knockdown in breast cancer cells, migration and invasion assays","journal":"Signal transduction and targeted therapy","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — Co-IP showing protein interaction, ubiquitination assay showing functional consequence, multiple orthogonal methods in single study","pmids":["35484112"],"is_preprint":false},{"year":2019,"finding":"OVOL1 represses ZEB1 expression by directly binding to the promoter region of ZEB1, thereby suppressing oral squamous cell carcinoma cell proliferation, migration, and invasion.","method":"ChIP assay, reporter assays, OVOL1 overexpression and ZEB1 rescue experiments in OSCC cell line","journal":"International journal of clinical and experimental pathology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP showing direct promoter binding, functional rescue with ZEB1 re-expression, single lab","pmids":["31934116"],"is_preprint":false},{"year":2009,"finding":"Neurogenin-3 (NGN3) negatively regulates Ovol1 transcription in an E-box-dependent fashion in rodent pancreas; NEUROD1 (but not MYOD) also reduces endogenous Ovol1 mRNA.","method":"Chromatin immunoprecipitation cloning, transactivation reporter assays, immunostaining of embryonic and adult rodent pancreas","journal":"Diabetologia","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP-cloning identified direct target, reporter assays confirmed E-box-dependent regulation, single lab with two orthogonal methods","pmids":["19882138"],"is_preprint":false},{"year":2019,"finding":"Jarid1b promotes epidermal differentiation by repressing Ship1 (via H3K4me3 demethylation at its promoter), activating the AKT pathway, which in turn increases Ovol1 expression to promote differentiation gene expression.","method":"ChIP for H3K4me3, knockdown/overexpression of Jarid1b and Ship1, PI3K-AKT pathway inhibitors, chamber graft model","journal":"Cell proliferation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP, pathway inhibitors, and in vivo graft model establish pathway placement; OVOL1 shown as downstream of AKT, single lab","pmids":["31152465"],"is_preprint":false},{"year":2017,"finding":"OVOL1 knockdown in squamous cell carcinoma cells increases mRNA and protein levels of c-Myc and OVOL2, while OVOL2 knockdown does not affect c-Myc or OVOL1 levels, establishing OVOL1 as an upstream suppressor of both c-Myc and OVOL2.","method":"siRNA knockdown in human squamous cell carcinoma line (A431), RT-qPCR, western blot, immunohistochemistry","journal":"Modern pathology","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — epistatic hierarchy established by siRNA knockdown of each component separately, multiple readouts (mRNA and protein), single lab","pmids":["28339425"],"is_preprint":false},{"year":2021,"finding":"Skin epithelia-specific deletion of Ovol1 impairs epidermal barrier and aggravates psoriasis-like inflammation by enhancing neutrophil accumulation; Cxcl1 (a neutrophil-attracting chemokine) was identified as a direct target of Ovol1 repression, and IL-33 as a weaker direct target.","method":"Conditional (skin-specific) Ovol1 knockout mouse model, imiquimod-induced psoriasis, ChIP for direct target identification, bulk RNA-seq","journal":"The Journal of investigative dermatology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — tissue-specific KO with defined phenotype, ChIP confirming direct transcriptional targets, functional in vivo evidence, single lab with multiple orthogonal methods","pmids":["34461129"],"is_preprint":false},{"year":2025,"finding":"OVOL1/Ovol1 is a conserved and direct transcriptional target of AhR in epidermal keratinocytes; genome-wide identification of Ovol1 direct downstream targets identified Id1 as a key functional target for barrier maintenance and disease suppression; Ovol1 deletion in keratinocytes exacerbates AD-like inflammation and impairs AhR's barrier-promoting function.","method":"Direct AhR-target validation in keratinocytes, Ovol1 keratinocyte-specific knockout, genome-wide ChIP-seq for Ovol1 targets, in vivo AD model, single-cell analyses","journal":"Cellular & molecular immunology","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — genome-wide ChIP-seq for direct targets, keratinocyte-specific KO with in vivo phenotype, multiple orthogonal methods, published peer-reviewed","pmids":["39939818"],"is_preprint":false},{"year":2026,"finding":"OVOL1 represses YAP transcription through an HDAC-dependent mechanism in esophageal squamous cell carcinoma, suppressing tumor cell proliferation, stemness, and metastasis.","method":"Luciferase reporter assay, co-immunoprecipitation, ChIP, RNA-seq, in vitro and in vivo (tail vein injection) functional experiments","journal":"Cellular signalling","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP and reporter assays for direct YAP transcriptional repression, HDAC-dependence tested, in vivo model, single lab","pmids":["42217551"],"is_preprint":false},{"year":2026,"finding":"OVOL1 promotes SPINK7 transcriptional activity; IL-13 abrogates nuclear translocation of OVOL1 and promotes enhanced degradation of OVOL1 protein via the esophageal-specific cysteine protease calpain-14, thereby suppressing SPINK7 expression and impairing epithelial barrier.","method":"OVOL1 overexpression and depletion assays, SPINK7 promoter luciferase reporter, nuclear translocation assays, IL-13 stimulation with calpain-14 inhibition, human esophageal biopsies","journal":"JCI insight","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reporter assay for SPINK7 promoter activity, nuclear translocation assay, calpain-14 pharmacological inhibition linking to OVOL1 degradation, single lab","pmids":["42048165"],"is_preprint":false},{"year":2025,"finding":"IFITM1 promotes limbal epithelial stem/early transient amplifying (eTA) cell expansion in part by inhibiting OVOL1, a negative regulator of epithelial cell proliferation; IFITM1 knockdown attenuates stem/eTA cell expansion after corneal wounding.","method":"AAV-mediated in vivo knockdown, single-cell RNA-seq, human limbal epithelial cell cultures","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — in vivo AAV knockdown with functional phenotype, cell culture experiments, OVOL1 identified as downstream effector but direct IFITM1-OVOL1 mechanism not fully resolved","pmids":["40372397"],"is_preprint":false},{"year":2025,"finding":"OVOL1 increases APOE expression and modulates cholesterol reprogramming to enhance proliferation and metastasis of non-small cell lung cancer cells both in vitro and in vivo.","method":"Functional assays in NSCLC cell lines, in vivo xenograft, APOE expression measurement after OVOL1 manipulation","journal":"Journal of cellular and molecular medicine","confidence":"Low","confidence_rationale":"Tier 3 / Weak — functional assays and APOE expression change shown, but direct mechanism linking OVOL1 to APOE transcription not established by ChIP or reporter in abstract","pmids":["40437660"],"is_preprint":false}],"current_model":"OVOL1 is a C2H2 zinc-finger transcriptional repressor that directly binds promoters of target genes—including c-Myc, Id2, ZEB1, Ovol2, Cxcl1, Id1, YAP, and SPINK7—to suppress their transcription, often recruiting HDAC activity via an N-terminal SNAG domain; it auto-represses its own promoter by competing with c-Myb for DNA binding; it is itself a direct transcriptional target of AhR signaling and is negatively regulated by NGN3 and by IL-13-triggered calpain-14-mediated protein degradation; and at the protein level it stabilizes SMAD7 by preventing its ubiquitination, thereby attenuating TGF-β receptor signaling, collectively positioning OVOL1 as a central node that enforces epithelial identity, mediates mesenchymal-to-epithelial transition, and maintains epidermal barrier and immune homeostasis."},"narrative":{"mechanistic_narrative":"OVOL1 is a C2H2 zinc-finger transcriptional repressor that enforces epithelial identity and terminal differentiation by directly binding promoters of proliferation- and mesenchymal-program genes to suppress their transcription [PMID:16636146, PMID:31934116]. During the proliferation-to-differentiation switch in epidermal progenitors it directly represses c-Myc to drive growth arrest [PMID:16636146], and it represses Id2 in spermatocytes where its loss blocks meiotic progression [PMID:15716349]; repression is implemented in part through an N-terminal SNAG domain that recruits HDAC activity, a mechanism OVOL1 also uses to auto-repress its own promoter by competing with the activator c-Myb [PMID:17311813]. OVOL1 sits within a self-limiting epithelial regulatory network, directly repressing OVOL2 [PMID:17049212, PMID:28339425] and the EMT driver ZEB1 to promote mesenchymal-to-epithelial transition and curb cancer cell migration and invasion [PMID:24124593, PMID:31934116], and repressing the Hippo effector YAP through an HDAC-dependent mechanism to suppress squamous carcinoma stemness and metastasis [PMID:42217551]. In skin, OVOL1 is a conserved direct transcriptional target of AhR signaling and acts downstream of AhR to maintain the epidermal barrier and restrain inflammation, repressing the neutrophil chemokine Cxcl1 and engaging Id1 as a key barrier-maintaining effector; its keratinocyte-specific loss aggravates psoriasis- and atopic-dermatitis-like inflammation [PMID:28703805, PMID:34461129, PMID:39939818]. Beyond transcriptional repression, OVOL1 also acts at the protein level, binding SMAD7 to block its ubiquitination and thereby attenuating TGF-β/SMAD signaling within a BMP-driven positive feedback loop [PMID:35484112]. OVOL1 activity is itself constrained by signals that block its nuclear translocation or trigger its degradation, including IL-4 and IL-13/calpain-14, the latter coupling cytokine signaling to loss of OVOL1-dependent SPINK7 expression and barrier impairment [PMID:28703805, PMID:42048165].","teleology":[{"year":2005,"claim":"Established OVOL1 as a transcriptional repressor with a defined developmental role by showing it silences Id2 to permit meiotic progression, framing the protein as a gatekeeper of cell-state transitions.","evidence":"Ovol1 knockout mouse, transcriptional profiling and reporter assays in pachytene spermatocytes","pmids":["15716349"],"confidence":"High","gaps":["Did not define the DNA-binding sequence or repression domain","Mechanism of cyclin B1 mislocalization downstream of Id2 left open"]},{"year":2006,"claim":"Showed OVOL1 directly represses c-Myc and Ovol2 promoters, linking it mechanistically to the proliferation-to-differentiation switch in epidermal progenitors and revealing a repressive regulatory cascade among OVOL family members.","evidence":"ChIP, reporter assays with DNA-binding mutants, Ovol1 knockout keratinocyte proliferation assays","pmids":["16636146","17049212"],"confidence":"High","gaps":["Did not identify the co-repressor machinery recruited to these promoters","Direct vs indirect effects on broader differentiation program not fully separated"]},{"year":2007,"claim":"Resolved the repression mechanism by identifying the N-terminal SNAG domain as an HDAC-recruiting module and demonstrating auto-repression via competition with the activator c-Myb, explaining how OVOL1 levels are self-limited.","evidence":"ChIP for histone acetylation and c-Myb/Ovol1 occupancy, domain mutagenesis, reporter assays","pmids":["17311813"],"confidence":"High","gaps":["Specific HDAC isoform not identified","Whether SNAG-HDAC recruitment operates at all OVOL1 target genes not tested"]},{"year":2009,"claim":"Placed OVOL1 within an upstream regulatory hierarchy by showing NGN3 and NEUROD1 repress its transcription in an E-box-dependent manner, extending OVOL1 regulation beyond epithelia.","evidence":"ChIP-cloning and transactivation reporter assays in rodent pancreas","pmids":["19882138"],"confidence":"Medium","gaps":["Functional consequence of OVOL1 repression in pancreas not established","Single lab, model-organism context"]},{"year":2013,"claim":"Connected OVOL1 to cancer cell-state control by demonstrating it drives mesenchymal-to-epithelial transition through a feedback loop with ZEB1 and induction of ESRP1, suppressing metastatic potential.","evidence":"Overexpression in cancer cells, mouse prostate tumor models, expression analysis across 917 cell lines","pmids":["24124593"],"confidence":"Medium","gaps":["Molecular mechanism of ZEB1 regulation not resolved at this stage","Direct vs indirect ESRP1 induction unclear"]},{"year":2017,"claim":"Defined the AhR→OVOL1→filaggrin axis in keratinocytes and showed IL-4 blocks OVOL1 nuclear translocation, establishing OVOL1 as a cytokine-controlled barrier regulator and an effector of skin immune homeostasis.","evidence":"Gain/loss-of-function in NHEKs, AHR ligand treatment, nuclear translocation assays; siRNA epistasis in A431 cells","pmids":["28703805","28339425"],"confidence":"High","gaps":["Whether FLG regulation is direct not shown","Mechanism by which IL-4 blocks nuclear import not defined"]},{"year":2019,"claim":"Confirmed direct ZEB1 promoter repression by OVOL1 and placed OVOL1 downstream of a Jarid1b-AKT axis, integrating chromatin and signaling inputs into epithelial differentiation control.","evidence":"ChIP and reporter assays with ZEB1 rescue in OSCC; ChIP for H3K4me3 and PI3K-AKT inhibitors in epidermal grafts","pmids":["31934116","31152465"],"confidence":"Medium","gaps":["How AKT increases OVOL1 expression not mechanistically defined","Single-lab findings"]},{"year":2021,"claim":"Demonstrated in vivo that epidermal OVOL1 maintains barrier integrity and restrains psoriasis-like inflammation by directly repressing the neutrophil chemokine Cxcl1, linking OVOL1 loss to a defined inflammatory phenotype.","evidence":"Skin-specific Ovol1 knockout, imiquimod psoriasis model, ChIP, bulk RNA-seq","pmids":["34461129"],"confidence":"High","gaps":["Relative contribution of Cxcl1 vs other targets to phenotype not quantified","IL-33 only weakly direct"]},{"year":2022,"claim":"Revealed a non-transcriptional mechanism whereby OVOL1 stabilizes SMAD7 by preventing its ubiquitination, thereby attenuating TGF-β receptor signaling within a BMP-driven positive feedback loop.","evidence":"Co-immunoprecipitation, ubiquitination assays, overexpression/knockdown with migration/invasion assays in breast cancer cells","pmids":["35484112"],"confidence":"High","gaps":["Co-IP without reciprocal endogenous validation","How OVOL1 shields SMAD7 from the E3 ligase not defined"]},{"year":2025,"claim":"Used genome-wide ChIP-seq to define OVOL1's direct target landscape and established it as a conserved AhR target essential for AhR's barrier-promoting function, identifying Id1 as a key effector.","evidence":"Genome-wide ChIP-seq, keratinocyte-specific knockout, in vivo AD model, single-cell analyses","pmids":["39939818"],"confidence":"High","gaps":["Functional role of most genome-wide targets not individually validated","Mechanism by which Id1 maintains barrier not detailed"]},{"year":2026,"claim":"Extended OVOL1's repressive program to the Hippo effector YAP and to SPINK7 activation, and showed IL-13/calpain-14 degrades OVOL1 to impair the esophageal barrier, unifying its tumor-suppressive and barrier-maintaining roles under cytokine control.","evidence":"ChIP/reporter/Co-IP in ESCC; SPINK7 reporter, nuclear translocation, calpain-14 inhibition in esophageal biopsies","pmids":["42217551","42048165"],"confidence":"Medium","gaps":["SPINK7 regulation shown as activation, contrasting OVOL1's repressor role, mechanism unresolved","Single-lab findings"]},{"year":null,"claim":"How OVOL1 switches between transcriptional repression of most targets and apparent activation of SPINK7, and what determines its context-dependent tumor-suppressive versus tumor-promoting roles, remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model for repressor vs activator behavior","Direct transcriptional control of metabolic targets such as APOE not established by ChIP","Structural basis of DNA recognition and co-factor switching unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,1,2,3,7,11,12,13]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[0,2,3,7,11]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[6]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[5,14]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,2,11,12]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[6,13]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[11,12,14]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[0,1,5]}],"complexes":[],"partners":["SMAD7","MYB"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"O14753","full_name":"Putative transcription factor Ovo-like 1","aliases":[],"length_aa":267,"mass_kda":30.3,"function":"Putative transcription factor. Involved in hair formation and spermatogenesis. May function in the differentiation and/or maintenance of the urogenital system (By similarity)","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/O14753/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/OVOL1","classification":"Not Classified","n_dependent_lines":4,"n_total_lines":1208,"dependency_fraction":0.0033112582781456954},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/OVOL1","total_profiled":1310},"omim":[{"mim_id":"602313","title":"OVO-LIKE 1; OVOL1","url":"https://www.omim.org/entry/602313"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Nucleoplasm","reliability":"Approved"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"esophagus","ntpm":55.4},{"tissue":"skin 1","ntpm":49.1},{"tissue":"testis","ntpm":33.8}],"url":"https://www.proteinatlas.org/search/OVOL1"},"hgnc":{"alias_symbol":["HOVO1"],"prev_symbol":[]},"alphafold":{"accession":"O14753","domains":[{"cath_id":"3.30.160","chopping":"207-241","consensus_level":"medium","plddt":75.9037,"start":207,"end":241}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O14753","model_url":"https://alphafold.ebi.ac.uk/files/AF-O14753-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O14753-F1-predicted_aligned_error_v6.png","plddt_mean":60.06},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=OVOL1","jax_strain_url":"https://www.jax.org/strain/search?query=OVOL1"},"sequence":{"accession":"O14753","fasta_url":"https://rest.uniprot.org/uniprotkb/O14753.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O14753/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O14753"}},"corpus_meta":[{"pmid":"24124593","id":"PMC_24124593","title":"Transcription factors OVOL1 and OVOL2 induce the mesenchymal to epithelial transition in human cancer.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24124593","citation_count":198,"is_preprint":false},{"pmid":"28703805","id":"PMC_28703805","title":"Aryl hydrocarbon receptor activation restores filaggrin expression via OVOL1 in atopic dermatitis.","date":"2017","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/28703805","citation_count":120,"is_preprint":false},{"pmid":"16636146","id":"PMC_16636146","title":"Ovol1 regulates the growth arrest of embryonic epidermal progenitor cells and represses c-myc transcription.","date":"2006","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/16636146","citation_count":111,"is_preprint":false},{"pmid":"31509236","id":"PMC_31509236","title":"The IL-13-OVOL1-FLG axis in atopic dermatitis.","date":"2019","source":"Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31509236","citation_count":85,"is_preprint":false},{"pmid":"15716349","id":"PMC_15716349","title":"Ovol1 regulates meiotic pachytene progression during spermatogenesis by repressing Id2 expression.","date":"2005","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/15716349","citation_count":56,"is_preprint":false},{"pmid":"17049212","id":"PMC_17049212","title":"Strain-dependent perinatal lethality of Ovol1-deficient mice and identification of Ovol2 as a downstream target of Ovol1 in skin epidermis.","date":"2006","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/17049212","citation_count":55,"is_preprint":false},{"pmid":"29866992","id":"PMC_29866992","title":"Upregulation of FLG, LOR, and IVL Expression by Rhodiola crenulata Root Extract via Aryl Hydrocarbon Receptor: Differential Involvement of OVOL1.","date":"2018","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/29866992","citation_count":47,"is_preprint":false},{"pmid":"29454536","id":"PMC_29454536","title":"The role of the OVOL1-OVOL2 axis in normal and diseased human skin.","date":"2018","source":"Journal of dermatological science","url":"https://pubmed.ncbi.nlm.nih.gov/29454536","citation_count":45,"is_preprint":false},{"pmid":"29972223","id":"PMC_29972223","title":"Antioxidative Phytochemicals Accelerate Epidermal Terminal Differentiation via the AHR-OVOL1 Pathway: Implications for Atopic Dermatitis.","date":"2018","source":"Acta dermato-venereologica","url":"https://pubmed.ncbi.nlm.nih.gov/29972223","citation_count":36,"is_preprint":false},{"pmid":"35484112","id":"PMC_35484112","title":"OVOL1 inhibits breast cancer cell invasion by enhancing the degradation of TGF-β type I receptor.","date":"2022","source":"Signal transduction and targeted therapy","url":"https://pubmed.ncbi.nlm.nih.gov/35484112","citation_count":35,"is_preprint":false},{"pmid":"17311813","id":"PMC_17311813","title":"Ovol1 represses its own transcription by competing with transcription activator c-Myb and by recruiting histone deacetylase activity.","date":"2007","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/17311813","citation_count":35,"is_preprint":false},{"pmid":"28892018","id":"PMC_28892018","title":"Antioxidant Artemisia princeps Extract Enhances the Expression of Filaggrin and Loricrin via the AHR/OVOL1 Pathway.","date":"2017","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/28892018","citation_count":34,"is_preprint":false},{"pmid":"28339425","id":"PMC_28339425","title":"Potential role of the OVOL1-OVOL2 axis and c-Myc in the progression of cutaneous squamous cell carcinoma.","date":"2017","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/28339425","citation_count":32,"is_preprint":false},{"pmid":"32932250","id":"PMC_32932250","title":"OVOL1/2: Drivers of Epithelial Differentiation in Development, Disease, and Reprogramming.","date":"2020","source":"Cells, tissues, organs","url":"https://pubmed.ncbi.nlm.nih.gov/32932250","citation_count":31,"is_preprint":false},{"pmid":"26873447","id":"PMC_26873447","title":"Activation of the OVOL1-OVOL2 Axis in the Hair Bulb and in Pilomatricoma.","date":"2016","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/26873447","citation_count":24,"is_preprint":false},{"pmid":"39939818","id":"PMC_39939818","title":"The AhR-Ovol1-Id1 regulatory axis in keratinocytes promotes epidermal and immune homeostasis in atopic dermatitis-like skin inflammation.","date":"2025","source":"Cellular & molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/39939818","citation_count":21,"is_preprint":false},{"pmid":"33333123","id":"PMC_33333123","title":"OVOL1 Regulates Psoriasis-Like Skin Inflammation and Epidermal Hyperplasia.","date":"2020","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/33333123","citation_count":21,"is_preprint":false},{"pmid":"23278845","id":"PMC_23278845","title":"Association of KIF3A, but not OVOL1 and ACTL9, with atopic eczema in Italian patients.","date":"2013","source":"The British journal of dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/23278845","citation_count":17,"is_preprint":false},{"pmid":"34461129","id":"PMC_34461129","title":"Epidermis-Intrinsic Transcription Factor Ovol1 Coordinately Regulates Barrier Maintenance and Neutrophil Accumulation in Psoriasis-Like Inflammation.","date":"2021","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/34461129","citation_count":14,"is_preprint":false},{"pmid":"31934116","id":"PMC_31934116","title":"OVOL1 inhibits oral squamous cell carcinoma growth and metastasis by suppressing zinc finger E-box binding homeobox 1.","date":"2019","source":"International journal of clinical and experimental pathology","url":"https://pubmed.ncbi.nlm.nih.gov/31934116","citation_count":14,"is_preprint":false},{"pmid":"30639212","id":"PMC_30639212","title":"OVOL1 Influences the Determination and Expansion of iPSC Reprogramming Intermediates.","date":"2019","source":"Stem cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/30639212","citation_count":13,"is_preprint":false},{"pmid":"31152465","id":"PMC_31152465","title":"Jarid1b promotes epidermal differentiation by mediating the repression of Ship1 and activation of the AKT/Ovol1 pathway.","date":"2019","source":"Cell proliferation","url":"https://pubmed.ncbi.nlm.nih.gov/31152465","citation_count":12,"is_preprint":false},{"pmid":"37249012","id":"PMC_37249012","title":"Ovol1/2 loss-induced epidermal defects elicit skin immune activation and alter global metabolism.","date":"2023","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/37249012","citation_count":9,"is_preprint":false},{"pmid":"25509883","id":"PMC_25509883","title":"Preferential expression of OVOL1 in inner root sheath of hair, sebaceous gland, eccrine duct and their neoplasms in human skin.","date":"2014","source":"Fukuoka igaku zasshi = Hukuoka acta medica","url":"https://pubmed.ncbi.nlm.nih.gov/25509883","citation_count":8,"is_preprint":false},{"pmid":"35787378","id":"PMC_35787378","title":"OVOL1 immunohistochemical expression is a useful tool to diagnose invasion in ocular surface squamous neoplasms.","date":"2022","source":"Archivos de la Sociedad Espanola de Oftalmologia","url":"https://pubmed.ncbi.nlm.nih.gov/35787378","citation_count":5,"is_preprint":false},{"pmid":"19882138","id":"PMC_19882138","title":"OVO homologue-like 1 (Ovol1) transcription factor: a novel target of neurogenin-3 in rodent pancreas.","date":"2009","source":"Diabetologia","url":"https://pubmed.ncbi.nlm.nih.gov/19882138","citation_count":3,"is_preprint":false},{"pmid":"40372397","id":"PMC_40372397","title":"IFITM1/OVOL1 Axis Is a Novel Regulator of the Expansion of the Limbal Epithelial Stem/Early Transient Amplifying Cell Population.","date":"2025","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/40372397","citation_count":3,"is_preprint":false},{"pmid":"38907248","id":"PMC_38907248","title":"Evaluation of OVOL1 and Filaggrin immunohistochemical expression and clinical relevance in psoriasis.","date":"2024","source":"Diagnostic pathology","url":"https://pubmed.ncbi.nlm.nih.gov/38907248","citation_count":2,"is_preprint":false},{"pmid":"38352592","id":"PMC_38352592","title":"An AhR-Ovol1-Id1 regulatory axis in keratinocytes promotes skin homeostasis against atopic dermatitis.","date":"2024","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/38352592","citation_count":2,"is_preprint":false},{"pmid":"40437660","id":"PMC_40437660","title":"OVOL1 Promotes Proliferation and Metastasis of Non-Small Cell Lung Cancer by Regulating APOE-Mediated Cholesterol Metabolism.","date":"2025","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/40437660","citation_count":1,"is_preprint":false},{"pmid":"42048165","id":"PMC_42048165","title":"IL-13 and calpain-14 suppress the expression of SPINK7 by regulating OVOL1 in eosinophilic esophagitis.","date":"2026","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/42048165","citation_count":0,"is_preprint":false},{"pmid":"42217551","id":"PMC_42217551","title":"OVOL1 targets YAP to suppress esophageal squamous cell carcinoma progression.","date":"2026","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/42217551","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":16838,"output_tokens":4050,"usd":0.055632,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":11948,"output_tokens":4009,"usd":0.079982,"stage2_stop_reason":"end_turn"},"total_usd":0.135614,"stage1_batch_id":"msgbatch_013a8chtv3AWyTqv4z4sEF4C","stage2_batch_id":"msgbatch_01AHsuW63vinsvuTgzmQ3n62","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2006,\n      \"finding\": \"Ovol1 represses c-myc transcription by directly binding to the c-myc promoter, thereby promoting growth arrest of embryonic epidermal progenitor cells transitioning from proliferation to terminal differentiation.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP), reporter assays, Ovol1 knockout mouse model with keratinocyte proliferation assays\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — direct promoter binding shown by ChIP, functional rescue experiments in KO model, multiple orthogonal methods\",\n      \"pmids\": [\"16636146\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Ovol1 represses Id2 (inhibitor of differentiation 2) transcription in pachytene spermatocytes, and its loss causes failure to progress through the pachytene stage of meiotic prophase accompanied by aberrant cyclin B1 nuclear localization.\",\n      \"method\": \"Ovol1 knockout mouse model, transcriptional profiling, northern blot, reporter assays\",\n      \"journal\": \"Development (Cambridge, England)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — KO model with defined cellular phenotype, reporter assays confirming Id2 as direct target, multiple orthogonal methods\",\n      \"pmids\": [\"15716349\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Ovol1 represses its own transcription (auto-repression) by: (1) competing with transcription activator c-Myb for DNA binding at its promoter, and (2) recruiting histone deacetylase (HDAC) activity via an N-terminal SNAG repressor domain.\",\n      \"method\": \"Reporter assays, chromatin immunoprecipitation (ChIP) for histone acetylation and c-Myb/Ovol1 occupancy, domain mutagenesis\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — multiple orthogonal methods (ChIP, reporter assays, domain mutagenesis) in single study\",\n      \"pmids\": [\"17311813\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Ovol1 represses Ovol2 promoter activity in a DNA binding-dependent manner; Ovol2 expression is upregulated in Ovol1-deficient epidermis, identifying Ovol2 as a direct downstream transcriptional target of Ovol1.\",\n      \"method\": \"Ovol1 knockout mouse model, reporter assays with Ovol2 promoter, DNA-binding mutant analysis\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — KO model plus reporter assay with DNA-binding mutant, single lab but two orthogonal methods\",\n      \"pmids\": [\"17049212\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"OVOL1 and OVOL2 induce mesenchymal-to-epithelial transition (MET) in human cancer cells through a regulatory feedback loop with EMT-inducing transcription factor ZEB1, and by inducing Epithelial Splicing Regulatory Protein 1 (ESRP1). Expression of OVOL-TFs in mesenchymal prostate cancer cells attenuates metastatic potential in mouse models.\",\n      \"method\": \"Overexpression in cancer cells, mouse prostate tumor models, expression analysis in 917 cancer cell lines\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — functional overexpression in cell lines and in vivo mouse model, but molecular mechanism of ZEB1 regulation not fully resolved at mechanistic detail level\",\n      \"pmids\": [\"24124593\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"AHR activation upregulates OVOL1 expression in keratinocytes, and OVOL1 in turn regulates filaggrin (FLG) expression; IL-4 treatment inhibits nuclear translocation of OVOL1 in an atopic dermatitis model.\",\n      \"method\": \"OVOL1 overexpression and knockdown in normal human epidermal keratinocytes (NHEKs), AHR ligand treatment, nuclear translocation assays\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain- and loss-of-function experiments with defined molecular pathway (AHR→OVOL1→FLG), nuclear translocation assay, single lab but multiple orthogonal approaches\",\n      \"pmids\": [\"28703805\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"OVOL1 interacts with and prevents ubiquitination and degradation of SMAD7, thereby stabilizing SMAD7 (a negative regulator of TGF-β type I receptor), leading to enhanced degradation of TGF-β type I receptor and inhibition of TGF-β/SMAD signaling. BMP promotes OVOL1 expression, which enhances BMP signaling in a positive feedback loop.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assays, overexpression/knockdown in breast cancer cells, migration and invasion assays\",\n      \"journal\": \"Signal transduction and targeted therapy\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — Co-IP showing protein interaction, ubiquitination assay showing functional consequence, multiple orthogonal methods in single study\",\n      \"pmids\": [\"35484112\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"OVOL1 represses ZEB1 expression by directly binding to the promoter region of ZEB1, thereby suppressing oral squamous cell carcinoma cell proliferation, migration, and invasion.\",\n      \"method\": \"ChIP assay, reporter assays, OVOL1 overexpression and ZEB1 rescue experiments in OSCC cell line\",\n      \"journal\": \"International journal of clinical and experimental pathology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP showing direct promoter binding, functional rescue with ZEB1 re-expression, single lab\",\n      \"pmids\": [\"31934116\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Neurogenin-3 (NGN3) negatively regulates Ovol1 transcription in an E-box-dependent fashion in rodent pancreas; NEUROD1 (but not MYOD) also reduces endogenous Ovol1 mRNA.\",\n      \"method\": \"Chromatin immunoprecipitation cloning, transactivation reporter assays, immunostaining of embryonic and adult rodent pancreas\",\n      \"journal\": \"Diabetologia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-cloning identified direct target, reporter assays confirmed E-box-dependent regulation, single lab with two orthogonal methods\",\n      \"pmids\": [\"19882138\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Jarid1b promotes epidermal differentiation by repressing Ship1 (via H3K4me3 demethylation at its promoter), activating the AKT pathway, which in turn increases Ovol1 expression to promote differentiation gene expression.\",\n      \"method\": \"ChIP for H3K4me3, knockdown/overexpression of Jarid1b and Ship1, PI3K-AKT pathway inhibitors, chamber graft model\",\n      \"journal\": \"Cell proliferation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP, pathway inhibitors, and in vivo graft model establish pathway placement; OVOL1 shown as downstream of AKT, single lab\",\n      \"pmids\": [\"31152465\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"OVOL1 knockdown in squamous cell carcinoma cells increases mRNA and protein levels of c-Myc and OVOL2, while OVOL2 knockdown does not affect c-Myc or OVOL1 levels, establishing OVOL1 as an upstream suppressor of both c-Myc and OVOL2.\",\n      \"method\": \"siRNA knockdown in human squamous cell carcinoma line (A431), RT-qPCR, western blot, immunohistochemistry\",\n      \"journal\": \"Modern pathology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — epistatic hierarchy established by siRNA knockdown of each component separately, multiple readouts (mRNA and protein), single lab\",\n      \"pmids\": [\"28339425\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Skin epithelia-specific deletion of Ovol1 impairs epidermal barrier and aggravates psoriasis-like inflammation by enhancing neutrophil accumulation; Cxcl1 (a neutrophil-attracting chemokine) was identified as a direct target of Ovol1 repression, and IL-33 as a weaker direct target.\",\n      \"method\": \"Conditional (skin-specific) Ovol1 knockout mouse model, imiquimod-induced psoriasis, ChIP for direct target identification, bulk RNA-seq\",\n      \"journal\": \"The Journal of investigative dermatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — tissue-specific KO with defined phenotype, ChIP confirming direct transcriptional targets, functional in vivo evidence, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"34461129\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"OVOL1/Ovol1 is a conserved and direct transcriptional target of AhR in epidermal keratinocytes; genome-wide identification of Ovol1 direct downstream targets identified Id1 as a key functional target for barrier maintenance and disease suppression; Ovol1 deletion in keratinocytes exacerbates AD-like inflammation and impairs AhR's barrier-promoting function.\",\n      \"method\": \"Direct AhR-target validation in keratinocytes, Ovol1 keratinocyte-specific knockout, genome-wide ChIP-seq for Ovol1 targets, in vivo AD model, single-cell analyses\",\n      \"journal\": \"Cellular & molecular immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — genome-wide ChIP-seq for direct targets, keratinocyte-specific KO with in vivo phenotype, multiple orthogonal methods, published peer-reviewed\",\n      \"pmids\": [\"39939818\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"OVOL1 represses YAP transcription through an HDAC-dependent mechanism in esophageal squamous cell carcinoma, suppressing tumor cell proliferation, stemness, and metastasis.\",\n      \"method\": \"Luciferase reporter assay, co-immunoprecipitation, ChIP, RNA-seq, in vitro and in vivo (tail vein injection) functional experiments\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP and reporter assays for direct YAP transcriptional repression, HDAC-dependence tested, in vivo model, single lab\",\n      \"pmids\": [\"42217551\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"OVOL1 promotes SPINK7 transcriptional activity; IL-13 abrogates nuclear translocation of OVOL1 and promotes enhanced degradation of OVOL1 protein via the esophageal-specific cysteine protease calpain-14, thereby suppressing SPINK7 expression and impairing epithelial barrier.\",\n      \"method\": \"OVOL1 overexpression and depletion assays, SPINK7 promoter luciferase reporter, nuclear translocation assays, IL-13 stimulation with calpain-14 inhibition, human esophageal biopsies\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reporter assay for SPINK7 promoter activity, nuclear translocation assay, calpain-14 pharmacological inhibition linking to OVOL1 degradation, single lab\",\n      \"pmids\": [\"42048165\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"IFITM1 promotes limbal epithelial stem/early transient amplifying (eTA) cell expansion in part by inhibiting OVOL1, a negative regulator of epithelial cell proliferation; IFITM1 knockdown attenuates stem/eTA cell expansion after corneal wounding.\",\n      \"method\": \"AAV-mediated in vivo knockdown, single-cell RNA-seq, human limbal epithelial cell cultures\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — in vivo AAV knockdown with functional phenotype, cell culture experiments, OVOL1 identified as downstream effector but direct IFITM1-OVOL1 mechanism not fully resolved\",\n      \"pmids\": [\"40372397\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"OVOL1 increases APOE expression and modulates cholesterol reprogramming to enhance proliferation and metastasis of non-small cell lung cancer cells both in vitro and in vivo.\",\n      \"method\": \"Functional assays in NSCLC cell lines, in vivo xenograft, APOE expression measurement after OVOL1 manipulation\",\n      \"journal\": \"Journal of cellular and molecular medicine\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — functional assays and APOE expression change shown, but direct mechanism linking OVOL1 to APOE transcription not established by ChIP or reporter in abstract\",\n      \"pmids\": [\"40437660\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"OVOL1 is a C2H2 zinc-finger transcriptional repressor that directly binds promoters of target genes—including c-Myc, Id2, ZEB1, Ovol2, Cxcl1, Id1, YAP, and SPINK7—to suppress their transcription, often recruiting HDAC activity via an N-terminal SNAG domain; it auto-represses its own promoter by competing with c-Myb for DNA binding; it is itself a direct transcriptional target of AhR signaling and is negatively regulated by NGN3 and by IL-13-triggered calpain-14-mediated protein degradation; and at the protein level it stabilizes SMAD7 by preventing its ubiquitination, thereby attenuating TGF-β receptor signaling, collectively positioning OVOL1 as a central node that enforces epithelial identity, mediates mesenchymal-to-epithelial transition, and maintains epidermal barrier and immune homeostasis.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"OVOL1 is a C2H2 zinc-finger transcriptional repressor that enforces epithelial identity and terminal differentiation by directly binding promoters of proliferation- and mesenchymal-program genes to suppress their transcription [#0, #7]. During the proliferation-to-differentiation switch in epidermal progenitors it directly represses c-Myc to drive growth arrest [#0], and it represses Id2 in spermatocytes where its loss blocks meiotic progression [#1]; repression is implemented in part through an N-terminal SNAG domain that recruits HDAC activity, a mechanism OVOL1 also uses to auto-repress its own promoter by competing with the activator c-Myb [#2]. OVOL1 sits within a self-limiting epithelial regulatory network, directly repressing OVOL2 [#3, #10] and the EMT driver ZEB1 to promote mesenchymal-to-epithelial transition and curb cancer cell migration and invasion [#4, #7], and repressing the Hippo effector YAP through an HDAC-dependent mechanism to suppress squamous carcinoma stemness and metastasis [#13]. In skin, OVOL1 is a conserved direct transcriptional target of AhR signaling and acts downstream of AhR to maintain the epidermal barrier and restrain inflammation, repressing the neutrophil chemokine Cxcl1 and engaging Id1 as a key barrier-maintaining effector; its keratinocyte-specific loss aggravates psoriasis- and atopic-dermatitis-like inflammation [#5, #11, #12]. Beyond transcriptional repression, OVOL1 also acts at the protein level, binding SMAD7 to block its ubiquitination and thereby attenuating TGF-\\u03b2/SMAD signaling within a BMP-driven positive feedback loop [#6]. OVOL1 activity is itself constrained by signals that block its nuclear translocation or trigger its degradation, including IL-4 and IL-13/calpain-14, the latter coupling cytokine signaling to loss of OVOL1-dependent SPINK7 expression and barrier impairment [#5, #14].\",\n  \"teleology\": [\n    {\n      \"year\": 2005,\n      \"claim\": \"Established OVOL1 as a transcriptional repressor with a defined developmental role by showing it silences Id2 to permit meiotic progression, framing the protein as a gatekeeper of cell-state transitions.\",\n      \"evidence\": \"Ovol1 knockout mouse, transcriptional profiling and reporter assays in pachytene spermatocytes\",\n      \"pmids\": [\"15716349\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define the DNA-binding sequence or repression domain\", \"Mechanism of cyclin B1 mislocalization downstream of Id2 left open\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Showed OVOL1 directly represses c-Myc and Ovol2 promoters, linking it mechanistically to the proliferation-to-differentiation switch in epidermal progenitors and revealing a repressive regulatory cascade among OVOL family members.\",\n      \"evidence\": \"ChIP, reporter assays with DNA-binding mutants, Ovol1 knockout keratinocyte proliferation assays\",\n      \"pmids\": [\"16636146\", \"17049212\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not identify the co-repressor machinery recruited to these promoters\", \"Direct vs indirect effects on broader differentiation program not fully separated\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Resolved the repression mechanism by identifying the N-terminal SNAG domain as an HDAC-recruiting module and demonstrating auto-repression via competition with the activator c-Myb, explaining how OVOL1 levels are self-limited.\",\n      \"evidence\": \"ChIP for histone acetylation and c-Myb/Ovol1 occupancy, domain mutagenesis, reporter assays\",\n      \"pmids\": [\"17311813\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific HDAC isoform not identified\", \"Whether SNAG-HDAC recruitment operates at all OVOL1 target genes not tested\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Placed OVOL1 within an upstream regulatory hierarchy by showing NGN3 and NEUROD1 repress its transcription in an E-box-dependent manner, extending OVOL1 regulation beyond epithelia.\",\n      \"evidence\": \"ChIP-cloning and transactivation reporter assays in rodent pancreas\",\n      \"pmids\": [\"19882138\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequence of OVOL1 repression in pancreas not established\", \"Single lab, model-organism context\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Connected OVOL1 to cancer cell-state control by demonstrating it drives mesenchymal-to-epithelial transition through a feedback loop with ZEB1 and induction of ESRP1, suppressing metastatic potential.\",\n      \"evidence\": \"Overexpression in cancer cells, mouse prostate tumor models, expression analysis across 917 cell lines\",\n      \"pmids\": [\"24124593\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular mechanism of ZEB1 regulation not resolved at this stage\", \"Direct vs indirect ESRP1 induction unclear\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Defined the AhR\\u2192OVOL1\\u2192filaggrin axis in keratinocytes and showed IL-4 blocks OVOL1 nuclear translocation, establishing OVOL1 as a cytokine-controlled barrier regulator and an effector of skin immune homeostasis.\",\n      \"evidence\": \"Gain/loss-of-function in NHEKs, AHR ligand treatment, nuclear translocation assays; siRNA epistasis in A431 cells\",\n      \"pmids\": [\"28703805\", \"28339425\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether FLG regulation is direct not shown\", \"Mechanism by which IL-4 blocks nuclear import not defined\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Confirmed direct ZEB1 promoter repression by OVOL1 and placed OVOL1 downstream of a Jarid1b-AKT axis, integrating chromatin and signaling inputs into epithelial differentiation control.\",\n      \"evidence\": \"ChIP and reporter assays with ZEB1 rescue in OSCC; ChIP for H3K4me3 and PI3K-AKT inhibitors in epidermal grafts\",\n      \"pmids\": [\"31934116\", \"31152465\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How AKT increases OVOL1 expression not mechanistically defined\", \"Single-lab findings\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Demonstrated in vivo that epidermal OVOL1 maintains barrier integrity and restrains psoriasis-like inflammation by directly repressing the neutrophil chemokine Cxcl1, linking OVOL1 loss to a defined inflammatory phenotype.\",\n      \"evidence\": \"Skin-specific Ovol1 knockout, imiquimod psoriasis model, ChIP, bulk RNA-seq\",\n      \"pmids\": [\"34461129\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution of Cxcl1 vs other targets to phenotype not quantified\", \"IL-33 only weakly direct\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Revealed a non-transcriptional mechanism whereby OVOL1 stabilizes SMAD7 by preventing its ubiquitination, thereby attenuating TGF-\\u03b2 receptor signaling within a BMP-driven positive feedback loop.\",\n      \"evidence\": \"Co-immunoprecipitation, ubiquitination assays, overexpression/knockdown with migration/invasion assays in breast cancer cells\",\n      \"pmids\": [\"35484112\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Co-IP without reciprocal endogenous validation\", \"How OVOL1 shields SMAD7 from the E3 ligase not defined\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Used genome-wide ChIP-seq to define OVOL1's direct target landscape and established it as a conserved AhR target essential for AhR's barrier-promoting function, identifying Id1 as a key effector.\",\n      \"evidence\": \"Genome-wide ChIP-seq, keratinocyte-specific knockout, in vivo AD model, single-cell analyses\",\n      \"pmids\": [\"39939818\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional role of most genome-wide targets not individually validated\", \"Mechanism by which Id1 maintains barrier not detailed\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Extended OVOL1's repressive program to the Hippo effector YAP and to SPINK7 activation, and showed IL-13/calpain-14 degrades OVOL1 to impair the esophageal barrier, unifying its tumor-suppressive and barrier-maintaining roles under cytokine control.\",\n      \"evidence\": \"ChIP/reporter/Co-IP in ESCC; SPINK7 reporter, nuclear translocation, calpain-14 inhibition in esophageal biopsies\",\n      \"pmids\": [\"42217551\", \"42048165\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"SPINK7 regulation shown as activation, contrasting OVOL1's repressor role, mechanism unresolved\", \"Single-lab findings\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How OVOL1 switches between transcriptional repression of most targets and apparent activation of SPINK7, and what determines its context-dependent tumor-suppressive versus tumor-promoting roles, remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model for repressor vs activator behavior\", \"Direct transcriptional control of metabolic targets such as APOE not established by ChIP\", \"Structural basis of DNA recognition and co-factor switching unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 1, 2, 3, 7, 11, 12, 13]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [0, 2, 3, 7, 11]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [6]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [5, 14]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 2, 11, 12]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [6, 13]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [11, 12, 14]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [0, 1, 5]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"SMAD7\", \"MYB\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":5,"faith_total":6,"faith_pct":83.33333333333333}}